Business
Marina Biotech Engages KCSA Strategic Communications as Investor Relations Counsel
Marina Biotech Engages KCSA Strategic Communications as Investor Relations Counsel.
About this update from Adhera Therapeutics Inc.
[{"type":"text","content":"\n\n\n\nMarina Biotech Engages KCSA Strategic Communications as Investor Relations Counsel\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nMarina Biotech Engages KCSA Strategic Communications as Investor Relations Counsel\nPR Newswire\nNEW YORK, Feb. 28, 2017\n\n\n\nNEW YORK, Feb. 28, 2017 /PRNewswire/ -- KCSA Strategic Communications, a leading New York-based communications firm, announced today that it has been selected to lead the investor relations program for Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer. \n\nKCSA intends to deploy an investor relations campaign designed to increase awareness of Marina Biotech among the investment community through a comprehensive communications strategy. KCSA's objectives include, among others, communications, strategy and introductions to the retail and institutional investment community. Since KCSA's inception nearly fifty years ago, the firm has developed a strong reputation for its work representing public companies. \n\nJoseph W. Ramelli, CEO of Marina Biotech, stated, \"We are excited to work with KCSA in order to build greater awareness of Marina Biotech with the investment community.  With a new and focused management team in place, we believe the Company is positioned to effectively tap into the significant development and partnership opportunities available through our pipeline of innovative therapeutics.  Marina Biotech offers investors an exciting opportunity to participate in the biotech sector, addressing the disease intersections of arthritis, hypertension and cancer through the use of combination therapies.\"\n\nTodd Fromer, Managing Partner of KCSA Strategic Communications, commented, \"With an extensive history of counseling  public companies, including healthcare, pharmaceutical and biotechnology companies, on their engagement of the investment community, we have developed a network of micro- and small cap investors that are looking for signif...